NVCN - Neovasc Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.0376
-0.0004 (-1.05%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.0380
Open0.0380
Bid0.0360 x 1300
Ask0.0379 x 2200
Day's Range0.0365 - 0.0393
52 Week Range0.0300 - 1.8900
Volume16,109,618
Avg. Volume88,157,023
Market Cap71.594M
Beta2.08
PE Ratio (TTM)N/A
EPS (TTM)-0.7240
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.88
Trade prices are not sourced from all markets
  • CNW Group8 hours ago

    Nasdaq Schedules Hearing to Consider Neovasc's Appeal of Delisting Determination

    VANCOUVER , July 16, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that The Nasdaq Stock Market LLC ("Nasdaq") has scheduled an oral hearing for August 30, 2018 , at which the Nasdaq Hearings Panel (the "Panel") will consider Neovasc's appeal of the Nasdaq Listing Qualifications Staff (the "Staff") decision to delist the Neovasc's securities from the Nasdaq Capital Market for non-compliance with the US$1.00 minimum bid price requirement. Words and phrases such as "believes", "can", "scheduled" and "will", and similar words or expressions, are intended to identify these forward-looking statements.

  • PR Newswire8 hours ago

    Nasdaq Schedules Hearing to Consider Neovasc's Appeal of Delisting Determination

    VANCOUVER, July 16, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that The Nasdaq Stock Market LLC ("Nasdaq") has scheduled an oral hearing for August 30, 2018, at which the Nasdaq Hearings Panel (the "Panel") will consider Neovasc's appeal of the Nasdaq Listing Qualifications Staff (the "Staff") decision to delist the Neovasc's securities from the Nasdaq Capital Market for non-compliance with the US$1.00 minimum bid price requirement. Words and phrases such as "believes", "can", "scheduled" and "will", and similar words or expressions, are intended to identify these forward-looking statements.

  • CNW Group17 hours ago

    Neovasc Announces Filing of "Administrative" Prospectus Supplement Relating to Expiry of Prior Shelf Prospectus / Registration Statement

    Neovasc Announces Filing of "Administrative" Prospectus Supplement Relating to Expiry of Prior Shelf Prospectus / Registration Statement

  • PR Newswire17 hours ago

    Neovasc Announces Filing of "Administrative" Prospectus Supplement Relating to Expiry of Prior Shelf Prospectus / Registration Statement

    NASDAQ, TSX: NVCN VANCOUVER , July 16, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that, in connection with its new final short ...

  • PR Newswire8 days ago

    Neovasc Receives Expected Delisting Determination from Nasdaq Staff and Will Request Nasdaq Hearing

    VANCOUVER, July 9, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will request a hearing before the Nasdaq Hearings Panel (the "Panel") as the next step in the process to seeking an additional 180-day extension for compliance with the US$1 minimum bid price requirement.  On July 6, 2018, the Company received the expected notice from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Staff has determined to delist the Company's common shares from Nasdaq Capital Market unless the Company requests a hearing before the Panel by July 13, 2018, which the Company will do. As previously announced, the Company has already received shareholder approval to execute a reverse stock split, common share consolidation, to enable the Company to regain compliance with the minimum bid price requirement.  However, the Company is seeking an additional 180-day extension so that the Board and management can effect the reverse stock split at a time, during that extension, if granted, that is in the best interest of the Company and its stakeholders.

  • CNW Group8 days ago

    Neovasc Receives Expected Delisting Determination from Nasdaq Staff and Will Request Nasdaq Hearing

    VANCOUVER , July 9, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will request a hearing before the Nasdaq Hearings Panel (the "Panel") as the next step in the process to seeking an additional 180-day extension for compliance with the US$1 minimum bid price requirement.  On July 6, 2018 , the Company received the expected notice from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Staff has determined to delist the Company's common shares from Nasdaq Capital Market unless the Company requests a hearing before the Panel by July 13, 2018 , which the Company will do. As previously announced, the Company has already received shareholder approval to execute a reverse stock split, common share consolidation, to enable the Company to regain compliance with the minimum bid price requirement.  However, the Company is seeking an additional 180-day extension so that the Board and management can effect the reverse stock split at a time, during that extension, if granted, that is in the best interest of the Company and its stakeholders.

  • CNW Group15 days ago

    Tiara and Reducer Featured at CSI Frankfurt 2018

    VANCOUVER , July 2, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TZX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Tiara™ ("Tiara"), a transcatheter treatment of mitral valve disease, and the Neovasc Reducer™ ("Reducer"), a CE-Marked medical devices used for the treatment of refractory angina, were both featured in presentations at the CSI Frankfurt 2018 conference held on June 27-30, 2018 in Frankfurt, Germany . This year, new Reducer clinical data was presented in a scientific session entitled: Structural meets coronary – Reducer for the treatment of refractory angina. The clinical data presented again demonstrated the clinical benefits of the Reducer in improving quality of life of patients suffering from disabling angina, as well as improving exercise capability.

  • PR Newswire15 days ago

    Tiara and Reducer Featured at CSI Frankfurt 2018

    VANCOUVER, July 2, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TZX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Tiara™ ("Tiara"), a transcatheter treatment of mitral valve disease, and the Neovasc Reducer™ ("Reducer"), a CE-Marked medical devices used for the treatment of refractory angina, were both featured in presentations at the CSI Frankfurt 2018 conference held on June 27-30, 2018 in Frankfurt, Germany. This year, new Reducer clinical data was presented in a scientific session entitled: Structural meets coronary – Reducer for the treatment of refractory angina. The clinical data presented again demonstrated the clinical benefits of the Reducer in improving quality of life of patients suffering from disabling angina, as well as improving exercise capability.

  • PR Newswire15 days ago

    Neovasc Announces Filing of Shelf Prospectus and Form F-10 Registration Statement

    VANCOUVER, July 2, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in Canada, other than Quebec, and a corresponding shelf registration statement on Form F-10 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") under the U.S./Canada Multijurisdictional Disclosure System. "This new base shelf prospectus will replace our existing base shelf prospectus that expires on July 9, 2018," commented Chris Clark, Neovasc's Chief Financial Officer. The base shelf prospectus and the Registration Statement, once clear and effective, respectively, will allow Neovasc to offer up to U.S.$100,000,000 of common shares, preferred shares, debt securities, subscription receipts, units and warrants from time to time over a 25-month period after Canadian securities regulatory authorities have issued a receipt for the final short form base shelf prospectus.

  • CNW Group15 days ago

    Neovasc Announces Filing of Shelf Prospectus and Form F-10 Registration Statement

    VANCOUVER , July 2, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in Canada , other than Quebec , and a corresponding shelf registration statement on Form F-10 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") under the U.S./Canada Multijurisdictional Disclosure System. "This new base shelf prospectus will replace our existing base shelf prospectus that expires on July 9, 2018 ," commented Chris Clark , Neovasc's Chief Financial Officer. The base shelf prospectus and the Registration Statement, once clear and effective, respectively, will allow Neovasc to offer up to U.S. $100,000 ,000 of common shares, preferred shares, debt securities, subscription receipts, units and warrants from time to time over a 25-month period after Canadian securities regulatory authorities have issued a receipt for the final short form base shelf prospectus.

  • Investopedia20 days ago

    Should You Snap up Medical Device Stock Neovasc Now?

    Neovasc Inc (NASDAQ: NVCN), a specialty medical device company that develops, manufactures and markets products for the cardiovascular segment of the healthcare market is witnessing great traction this week. The company has just announced its first patient implant using its flagship medical device, NVCN reducer. Here we use TipRanks data to take a closer look at what Wall Street’s top analysts see in store for this volatile stock.

  • PR Newswire25 days ago

    Tiara™ Featured in Live Case at 11th Annual TVT 2018

    VANCOUVER, June 21, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Tiara™ ("Tiara") transcatheter mitral valve replacement device was featured in a "Live Case" broadcast at the 11th Annual Transcatheter Valve Therapy Conference ("TVT 2018"). In a live case broadcast to the main arena of the conference, Dr. Anson Cheung, and Dr. John G. Webb of St. Paul's Hospital (Vancouver, Canada) successfully implanted a 40mm Tiara transcatheter mitral valve in a patient suffering from severe mitral regurgitation. The Heart Team weighed in on all available treatment options and determined the Tiara device was the best option for this patient.

  • CNW Group25 days ago

    Tiara™ Featured in Live Case at 11th Annual TVT 2018

    VANCOUVER , June 21, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Tiara™ ("Tiara") transcatheter mitral valve replacement device was featured in a "Live Case" broadcast at the 11th Annual Transcatheter Valve Therapy Conference ("TVT 2018"). In a live case broadcast to the main arena of the conference, Dr. Anson Cheung , and Dr. John G. Webb of St. Paul's Hospital ( Vancouver, Canada ) successfully implanted a 40mm Tiara transcatheter mitral valve in a patient suffering from severe mitral regurgitation. The Heart Team weighed in on all available treatment options and determined the Tiara device was the best option for this patient.

  • CNW Group27 days ago

    Neovasc Announces First Implant of a Neovasc Reducer™ in a U.S. Patient

    VANCOUVER , June 20, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced the first U.S. patient has been implanted with a Neovasc Reducer™ (the "Reducer"), a CE-Marked medical device for the treatment of refractory angina. Dr. Koenig commented "This patient has severe coronary artery disease and has suffered from refractory angina for a few years. My experience with the Reducer during the procedure, was very positive.

  • PR Newswire27 days ago

    Neovasc Announces First Implant of a Neovasc Reducer™ in a U.S. Patient

    VANCOUVER, June 20, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced the first U.S. patient has been implanted with a Neovasc Reducer™ (the "Reducer"), a CE-Marked medical device for the treatment of refractory angina. Dr. Koenig commented "This patient has severe coronary artery disease and has suffered from refractory angina for a few years. My experience with the Reducer during the procedure, was very positive.

  • ACCESSWIRE29 days ago

    Neovasc and Three Additional Medical Appliances & Equipment Stocks on Our Research Desk’s Radar

    This Monday, WallStEquities.com has initiated reports coverage on the following Medical Appliances & Equipment equities: Neovasc Inc. (NASDAQ: NVCN), Smith & Nephew PLC (NYSE: SNN), Accuray Inc. (NASDAQ: ARAY), and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). All you have to do is sign up today for this free limited time offer by clicking the link below.

  • PR Newswirelast month

    Neovasc Announces Appointment of Steve Rubin as Chairman of the Board and General Update

    VANCOUVER, June 11, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Board of Directors (the "Board") has elected Steve Rubin as Chairman of the Board, effective immediately. "I am honored to have the opportunity to work more closely with Fred and the rest of the Neovasc team as we advance the Company's development and commercial strategy for the Tiara and Reducer," stated Mr. Rubin.

  • CNW Grouplast month

    Neovasc Announces Appointment of Steve Rubin as Chairman of the Board and General Update

    VANCOUVER , June 11, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Board of Directors (the "Board") has elected Steve Rubin as Chairman of the Board, effective immediately. "I am honored to have the opportunity to work more closely with Fred and the rest of the Neovasc team as we advance the Company's development and commercial strategy for the Tiara and Reducer," stated Mr. Rubin.

  • Loss-Making Neovasc Inc (NASDAQ:NVCN) Expected To Breakeven
    Simply Wall St.last month

    Loss-Making Neovasc Inc (NASDAQ:NVCN) Expected To Breakeven

    Neovasc Inc’s (NASDAQ:NVCN): Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. The company’s loss has recently broadened since it announced a -US$22.91M loss inRead More...

  • CNW Grouplast month

    Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders

    Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders

  • CNW Group2 months ago

    Neovasc Provides Highlights from EuroPCR; Symposium Generates Increased Interest in Reducer

    VANCOUVER , May 25, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today provided highlights from EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology (ESC), which took place at the Palais des Congrès in Paris, France May 22-25 . "We had a successful and engaging meeting with investigators in our Tiara-II trial regarding clinical results to-date, optimal screening process, best practices for implantation, and a direct comparison of published Tiara clinical results with results from mitral clipping procedures," commented Fred Colen , Neovasc's Chief Executive Officer.

  • CNW Group2 months ago

    Neovasc's Management and Board of Directors Urge Shareholders to Vote In Favor of the Proposed Reverse Stock Split at the Upcoming Annual General and Special Meeting of Shareholders

    VANCOUVER , May 15, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its management and board of directors (the "Board") urge the Company's shareholders of record to vote "FOR" the proposal authorizing the Board to effect a reverse stock split. "Remaining on the Nasdaq Capital Market ("Nasdaq") is a critical piece of the Company's turnaround strategy," commented Fred Colen , Neovasc's President and Chief Executive Officer. "Without reaching a minimum bid price above US$1.00 for a minimum of 10 consecutive days before July 2, 2018 , the Company may be delisted from the Nasdaq, which would have serious consequences for the Company as further outlined in this press release.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Puma Biotechnology and Neovasc

    NEW YORK, NY / ACCESSWIRE / May 11, 2018 / Puma Biotechnology shares sank on Thursday after it revealed concerning information about Nerlynx, a prescription medicine used to treat adults who have early-stage breast cancer, as well as its first quarter earnings. Puma Biotechnology, Inc. shares closed down 20.67% on almost 5.5 million shares traded yesterday.

  • Associated Press2 months ago

    Neovasc: 1Q Earnings Snapshot

    On a per-share basis, the Richmond, British Columbia-based company said it had a loss of 38 cents. Losses, adjusted for amortization costs and non-recurring costs, came to 11 cents per share. The medical ...

  • CNW Group2 months ago

    Neovasc Announces Results for the First Quarter 2018

    VANCOUVER , May 10, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced financial results for the quarter ended March 31, 2018 (all figures in U.S. dollars unless otherwise indicated). "Despite a challenging period for our shareholders, we are encouraged by our improved financial position through the receipt of $12.3 million in proceeds from investor-initiated exercises of Series C warrants that were issued during our November 2017 public offering," commented Fred Colen , Neovasc's Chief Executive Officer.